| Revenue growth | Consolidated +25.1% YoY; standalone +26.8% YoY |
|---|---|
| Margins | Consolidated EBITDA margin 33.0%, flat YoY; gross margin +190 bps |
| Demand visibility | Franchisee additions ~1,180, highest in three years |
Growth
Consolidated revenue +25.1%, pathology +26.7%, EBITDA +25.0%; standalone revenue +26.8%. H1 consolidated revenue +24.7%.
Outlook
No explicit numeric guidance. Five new labs launched; ~1,180 franchisee additions; NHL sale proceeds ₹141.4 Cr if approved.
Risks
₹45 Cr consolidated NHL impairment; divestment needs shareholder approval; radiology revenue down 4.2%; rising opex from pregnancy kit launch.
Last quarter's promises, checked
Delivered
- Q2 franchisee adds guided 500 → ~1,180 (= BEAT)
- Franchisee growth guided mid-to-high teens → +27.1% YoY (= BEAT)
- Overall growth ~20% (analyst-cited) → consolidated +25.1% (= BEAT)
Partly delivered
- NHL exit ~6 months → still pending shareholder approval (= PARTIAL)
- Radiology FY PAT ~INR6 Cr → revenue -4.2%, PAT undisclosed (= PARTIAL)
Investor Presentation filed with NSE, NSE: THYROCARE. Summary written with AI assistance from the document.
Thyrocare Technologies Ltd: key numbers
- Share price
- ₹517.00
- Market cap
- ₹8,229 Cr
- Revenue (annual)
- ₹829.0 Cr
- Net profit (annual)
- ₹163.0 Cr
- P/E (TTM)
- 46.7×Sector 52.0×
- Promoter holding
- 51.02%-9.90% QoQ
- FII holding
- 9.37%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Thyrocare Technologies Ltd
All →Thyrocare Technologies Results Update
Thyrocare Technologies reported Q2FY27 consolidated revenue of Rs 270.8 Cr, up 25.1% YoY, with PAT before exceptions of Rs 60.2 Cr. The press release also notes a Rs 45 Cr non-cash NHL impairment tied to a proposed divestment.
Thyrocare Technologies Q2 FY27 Results: Net Profit ₹15.2 Cr, Down 68.2% YoY
Thyrocare Technologies Ltd reported revenue from operations of ₹270.8 Cr (+25.1% YoY) and net profit of ₹15.2 Cr (-68.2% YoY) for Q2 FY27.
- Key figure
- Net profit ₹15.2 Cr · -68.2% YoY
Thyrocare Technologies Board Meeting Date
Thyrocare Technologies intimated that its Board meeting is scheduled for 29 Oct 2026 to consider Q2/H1 FY27 results. No financial figures or decisions are reported in this prior intimation.
Thyrocare Technologies Other Announcement
Thyrocare Technologies filed its quarterly shareholding pattern for the period ended September 30, 2026, including a note regarding a prior promoter group amalgamation.
Thyrocare Technologies Annual General Meeting
Thyrocare Technologies initiated a postal ballot for two resolutions: purchasing property from its subsidiary, Nueclear Healthcare, and selling its investment in Nueclear Healthcare.
Thyrocare Technologies Annual General Meeting
Thyrocare seeks shareholder approval via postal ballot for the purchase of land and building and the divestment of its subsidiary, Nueclear Healthcare Limited.
- Value
- ₹162.0 Cr